A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506982-73-00

Acronym

Embrace-III Hi-Risk

Enrollment

Registered

2025-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

Brief summary

Actuarial Progression free survival (PFS) rate at 24 months

Interventions

DRUGLENVATINIB

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Actuarial Progression free survival (PFS) rate at 24 months	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026